Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.09 |
D007239 | Infection NIH | 0.06 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This is a multi-center, double-blinded, placebo-controlled parallel, phase II clinical efficacy study evaluating NORS for the treatment of COVID-19 in individuals with Suspected mild COVID-19 Infection.
Description: Number of subjects requiring hospitalization or ER/ED visits for COVID-19/flu-like symptoms in NORS vs placebo group
Measure: To Measure the efficacy of NORS compared to saline placebo in the hospitalization of participants with mild COVID-19 infection Time: 28 DaysDescription: Measure the change in mean Modified Jackson Cold Score Diary Score
Measure: To Measure reduction of clinical symptoms as compared to saline placebo in participants with mild COVID-19 infection Time: 7, 14, 21 and 28 daysDescription: Number of participants lost-to-follow-up,discontinuing study treatment or number of treatments due to intolerance
Measure: To measure the tolerance of NORS compared to saline placebo in participants with mild COVID-19 infection Time: 14 daysDescription: Severity and frequency of adverse events, pain, discomfort or discontinuations of treatment.
Measure: To measure the tolerance of NORS compared to saline placebo in participants with mild COVID-19 infection Time: 14 days